Hesperos and OYC formed a strategic channel sales partnership to make Human‑on‑a‑Chip® services more accessible to biopharma and research organizations in Japan and throughout Asia
Orlando, Florida & Tokyo, Japan – 23 October 2025 – Hesperos, Inc. (Hesperos), a global leader focused on improving preclinical drug development, food and chemical testing with its Human-on-a-Chip® (HoaC) single- and multi-organ systems platform is pleased to announce a strategic channel sales partnership with Oriental Yeast Co., Ltd. (OYC). OYC provides best-in-class bakery, nutraceuticals and food products coupled with a broad range of bioscience products and services all over the world with concentrated business in Japan, across Asia as well as Europe and the Americas.
This strategic partnership will have OYC proactively market Hesperos’ HoaC preclinical drug development platform services to biopharmaceutical and medical technology organizations throughout Asia.
Key Highlights
Hesperos and Oriental Yeast Co. established a strategic partnership to expand Human-on-a-Chip® services throughout Asia.
Strategic Partnership
Hesperos, Inc. is pleased to announce a strategic channel sales partnership with Oriental Yeast Co., Ltd. (OYC). OYC provides best-in-class bakery, nutraceuticals and food products coupled with a broad range of bioscience products and services all over the world.
Expanded Access to Services Across Asia
This strategic partnership will have OYC proactively market Hesperos’ HoaC preclinical drug development platform services to biopharmaceutical and medical technology organizations in Japan and throughout Asia.
Global Momentum: Advancing New Approach Methodologies (NAMs)
Across the world, regulatory agencies such as the U.S. FDA and NIH are encouraging the use of more predictive, human-relevant preclinical tools. Human-on-a-Chip® technology is a leading example of these New Approach Methodologies (NAMs), providing functional human data that can complement or replace certain animal studies.
Through this partnership, Hesperos and OYC are working to expand the global adoption of NAMs, helping biopharma organizations to:
- De-risk early decisions with translational human data
- Generate human-relevant safety and efficacy insights
- Shorten development timelines with more informative studies
- Reduce R&D costs through targeted, high-value experimentation
"This strategic partnership will permit us to better serve the region’s growing demand for human-based, organ-on-a-chip services in alignment with the mission of both organizations, to help to bring new, safe and effective treatments to patients faster."
Lawrence Florin
Chief Executive Officer
Hesperos, Inc.
"We are pleased to partner with Hesperos and bring their pioneering Human-on-a-Chip services to biotech and university researchers in Japan and across Asia."
Keiji Yamamoto
Head of the Bioindustry Division
Oriental Yeast Co., LTD.
Oriental Yeast Co., Ltd., Bioindustry Division
The Bioindustry Division of Oriental Yeast Co., Ltd. (OYC) is an industry leader in providing biochemicals, reagents, and specialized in vitro, ex vivo and in vivo services to support drug development and life science research. With over 90 years of research expertise, the division drives innovation in healthcare by developing, manufacturing and providing high-value biochemical products and services that are essential to advancing scientific discovery and therapeutic development. For more information, visit https://www.oyc.co.jp/en/bio/
Discover how we can advance your pipeline faster and more efficiently
Explore Other Hesperos News
Hesperos and Oriental Yeast Co., Ltd. Announce Strategic Partnership to Expand Human-on-a-Chip® Services Across Asia
Hesperos and Oriental Yeast Co. form a strategic partnership to expand access to Human-on-a-Chip® services across Asia, accelerating safer, more effective preclinical drug development.
